Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Creteil – page 12

644 clinical trials in Creteil, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Creteil at a glance
644
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

644 trials in Creteil

Open in trial search

Plasma cell myeloma

Recruiting

Study Comparing Elranatamab and Lenalidomide with Daratumumab and Lenalidomide for Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Asthma

Recruiting

Study on Stopping Dupilumab in Patients with Severe Asthma Who Have Been on the Drug for Over 3 Years

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Sickle cell disease

Recruiting

Study on How Well Etavopivat Works for Adolescents and Adults with Sickle Cell Disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Non-small cell lung cancer stage III

Recruiting

Study on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Pyrexia+1

Recruiting

Study on the Safety and Immune Response of the 20-Valent Pneumococcal Vaccine in Adults with Fever and High Risk for Pneumococcal Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Acute myeloid leukaemia

Recruiting

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Immune thrombocytopenia

Recruiting

Study on the Effectiveness and Safety of Efgartigimod IV for Adults with Primary Immune Thrombocytopenia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Small cell lung cancer limited stage

Recruiting

Study on Toripalimab and Tifcemalimab for Patients with Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tifcemalimab
  • Sponsor:Shanghai Junshi Biosciences Co. Ltd.

Dry age-related macular degeneration+1

Recruiting

Study of Pozelimab and Cemdisiran for Adults with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Cirrhosis alcoholic

Recruiting

Study on Carvedilol for Preventing Complications in Patients with Early-Stage Cirrhosis and High Blood Pressure in the Liver

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carvedilol
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Crohn's disease

Recruiting

Study on EXL01 for Preventing Crohn's Disease Recurrence After Surgery in Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:EXL01
  • Sponsor:Groupe De Recherche Sur Les Maladies Inflammatoires Digestives

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Creteil

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Groundbreaking studies focusing on TTR amyloidosis and heart disease treatments, evaluating novel therapeutic approaches for cardiac conditions. Research includes assessment of innovative medications for chronic kidney disease with hypertension.

  • TTR Amyloidosis Cardiomyopathy
  • Chronic Kidney Disease
  • Hypertension Management
02 Neurological Disorders

Comprehensive research into various neurological conditions, including innovative studies on Huntington's disease biomarkers and treatment approaches for essential tremor and Parkinson's disease.

  • Huntington's Disease Progression
  • Essential Tremor Treatment
  • Parkinson's Disease Management
03 Oncology & Hematology

Advanced clinical trials in blood cancers and solid tumors, including studies of multiple myeloma treatments and novel approaches for non-small cell lung cancer and mesothelioma.

  • Multiple Myeloma Therapies
  • Acute Myeloid Leukemia
  • Lung Cancer Treatment
04 Autoimmune Conditions

Innovative treatments for inflammatory and autoimmune disorders, investigating new therapies for Crohn's disease, ulcerative colitis, and rheumatoid arthritis.

  • Inflammatory Bowel Disease
  • Rheumatoid Arthritis Management
  • Microbiota Transplantation Studies
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.